Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Purchases of Investments

Cash used to buy marketable securities and other investments.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments declines year over year

Q1 FY2026 purchases of investments of $20.14M (cash outflow) fell 84.0% year over year, behind the -81.7% change in trailing-twelve-month purchases of investments. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.

Context

  • Purchases of investments grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -84.0% toward the trailing-twelve-month pace of -81.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$20.14M+2.7% QoQ
Last fiscal yearDec 2025
-$236.53M-67.2% YoY
LTMMar 2026
-$130.83M-81.7% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.0%——
1 year-67.2%——
3-year CAGR-14.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(236.53M) USD
Year-over-year change
+67.2%

Purchases of Investments vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -81.7% is the 8th highest of 9, against a peer median of -14.2%.
  • Over three fiscal years its annual growth of -14.5% compares with a peer median of +17.3%.
CGEM Competitors
Purchases of Investments for CGEM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$606.54M USD-87.5%+90.9%44.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$604.34M USD+4.3%+23.9%86.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$446.68M USD-32.7%+33.8%2066.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$327.5M USD+60.6%——
MGNXMacroGenics, Inc.LTM Mar 2026$202.4M USD+485.0%+20.0%128.9%
XNCRXencor, Inc.LTM Jun 2026$194.76M USD-62.0%-8.3%185.5%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$160.3M USD+74.4%-48.5%—
IMTXImmatics N.V.LTM Mar 2026€149.18M EUR-64.3%+14.5%400.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$130.83M USD-81.7%-14.5%—
CGENCompugen Ltd.LTM Dec 2025$0 USD—+7.7%0.0%
ADCTADC Therapeutics S.A.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CGEM) —-14.2%+17.3%107.5%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(67.49M)109.2M(153.16M)(167.58M)(219.88M)
Depreciation & Amortization53K93K310K306K311K
Deferred Income Tax3.1M0000
Stock-Based Compensation24.38M27.96M30.44M37.82M36.04M
Change in Working Capital(3.54M)11.18M(339K)(389K)14.08M
Accounts Receivables00000
Inventory00000
Accounts Payables(4.84M)(509K)(167K)(812K)(839K)
Other Working Capital1.29M11.69M(172K)423K14.92M
Other Non-Cash Items67K(275.09M)(11.52M)(15.47M)(6.31M)
Operating Cash Flow(43.43M)(126.66M)(134.28M)(145.3M)(175.75M)
Capital Expenditures(589.23K)(1.13M)(208K)0(49K)
Acquisitions (Net)923K275M(36.01K)00
Purchases of Investments(525.81M)(377.92M)(373.38M)(721.13M)(236.53M)
Sales of Investments192.04M352.93M409.4M584.82M416.57M
Other Investing Activities(333.78K)91K36.01K00
Investing Cash Flow(333.78M)248.98M35.81M(136.31M)179.99M
Debt Repayment0(2.2M)1.83M00
Common Stock Issued267.27M8.4M38.39M262.65M1.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M(32.13M)538K3.54M0
Financing Cash Flow268.78M(25.93M)40.75M266.19M1.09M
Effect of Forex Changes00000
Net Change in Cash(108.42M)96.38M(57.72M)(15.43M)5.33M
Free Cash Flow(44.02M)(127.8M)(134.48M)(145.3M)(175.8M)

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.